clinical trial · NCT07361705
Zorifertinib With Osimertinib for NSCLC With Meningeal Progression
Alpha Biopharma (Jiangsu) Co., Ltd.·phase1·not yet recruiting·n = 42
Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression After Osimertinib TreatmentZorifertinib and Osimertinib Combination Therapy
brief summary
This is a clinical trial that aims to test Zorifertinib when used together with a known drug, Osimertinib. The goal is to learn if this combination is safe and works for people with advanced Non-Small Cell Lung Cancer (NSCLC) whose cancer has spread to the membranes surrounding the brain and spinal cord (a condition called leptomeningeal metastases) after being treated with Osimertinib.
started
Jan 31, 2026
primary completion
Apr 23, 2028
completion
Sep 15, 2028
last updated
Jan 23, 2026
official title
An Open-Label, Multicentre, Phase 1 Clinical Study to Evaluate the Safety and Efficacy of Zorifertinib Combined With Osimertinib in Patients With Advanced Non-Small Cell Lung Cancer With Meningeal Progression After Osimertinib Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol